Meeting Report

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

Presented by Rasheda Persinger, AGNP-C

From Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, Baltimore, Maryland


J Adv Pract Oncol 2021;12(3):301–305 | https://doi.org/10.6004/jadpro.2021.12.3.17 | © 2021 Harborside™


  

ABSTRACT

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.